11.06.2019 DEINOVE and AVRIL completing the development of a natural feed additive The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...
05.06.2019 DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...
21.05.2019 Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...
20.05.2019 The US Department of Defense and Deinove will present impactful R&D results during the coming ASM 2019 The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...
16.05.2019 DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...
13.05.2019 The mechanism of action of Phytoene applied to dermocosmetic now determined and promoted at the NYSCC Suppliers' day DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism...
12.04.2019 DEINOVE invited to present at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming...
09.04.2019 Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal...
28.03.2019 2018 Annual Results: a year of significant progress Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...
21.03.2019 DEINOVE passes the first milestone of the AGIR program and receives €1.5m from Bpifrance The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of...